Scholar Rock Holding Corp. Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Scholar Rock Holding Corporation, a late-stage biopharmaceutical company dedicated to developing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious conditions influenced by protein growth factors, has announced the initiation of an underwritten public offering. The company aims to raise $275 million through the sale of its common stock, with the option for investors to choose pre-funded warrants as an alternative. All shares and pre-funded warrants will be offered by Scholar Rock. Additionally, the company plans to grant underwriters a 30-day option to purchase up to 15% more shares of common stock, based on the offering’s terms and market conditions. The completion, timing, and structure of the offering remain uncertain at this stage.

The net proceeds from this offering will be utilized to support the commercialization of apitegromab, advance ongoing and future clinical programs, further develop its technology platform, and for general working capital and corporate needs.

J.P. Morgan Securities LLC, Jefferies LLC, and Piper Sandler & Co. are serving as joint book-running managers for this offering, while BMO Capital Markets Corp., Wedbush Securities Inc., and Raymond James & Associates, Inc. are acting as co-managers.